This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://localhost/temp/predkladatel/
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F13%3A00069888%21RIV14-MSM-14110___/
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/resource/domain/vavai/subjekt/
n15http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n8http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F13%3A00069888%21RIV14-MSM-14110___
rdf:type
skos:Concept n15:Vysledek
dcterms:description
Older patients with AML have poor prognosis after chemotherapy and allo-SCT was historically limited to the young patients. In the multicentre retrospective study we analyzed 96 consecutive AML patients >= 50 years allografted with related (n=59) or unrelated (n=37) donor. The 2- year OS and DFS rates were 45 % and 42 % for the whole group. The corresponding figures for related patients were 48% and 42% whereas for unrelated 42% and 42%, respectively (OS p=0,721, DFS p = 0,896). The cumulative incidences of relapse (28% of all patients) and NRM mortality (26%) were low with no significant differences among related and unrelated cohorts. Multivariate analysis revealed the only major independent variables associated with an inferior OS were unfavourable cytogenetics (RR 3.36; CI 1.66-6.83; p=0.001) and advanced disease status (RR 2.30; CI 1.21-4.37; p=0.011). Unfavourable cytogenetics (RR 3.00; CI 1.50-5.99; p=0.002) and advanced disease at SCT (RR 2.27; CI 1.22-4.22; p=0. Older patients with AML have poor prognosis after chemotherapy and allo-SCT was historically limited to the young patients. In the multicentre retrospective study we analyzed 96 consecutive AML patients >= 50 years allografted with related (n=59) or unrelated (n=37) donor. The 2- year OS and DFS rates were 45 % and 42 % for the whole group. The corresponding figures for related patients were 48% and 42% whereas for unrelated 42% and 42%, respectively (OS p=0,721, DFS p = 0,896). The cumulative incidences of relapse (28% of all patients) and NRM mortality (26%) were low with no significant differences among related and unrelated cohorts. Multivariate analysis revealed the only major independent variables associated with an inferior OS were unfavourable cytogenetics (RR 3.36; CI 1.66-6.83; p=0.001) and advanced disease status (RR 2.30; CI 1.21-4.37; p=0.011). Unfavourable cytogenetics (RR 3.00; CI 1.50-5.99; p=0.002) and advanced disease at SCT (RR 2.27; CI 1.22-4.22; p=0.
dcterms:title
The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: An analysis of 96 allografted AML patients >= 50 years from the Czech acute leukaemia clinical register (alert) The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: An analysis of 96 allografted AML patients >= 50 years from the Czech acute leukaemia clinical register (alert)
skos:prefLabel
The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: An analysis of 96 allografted AML patients >= 50 years from the Czech acute leukaemia clinical register (alert) The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: An analysis of 96 allografted AML patients >= 50 years from the Czech acute leukaemia clinical register (alert)
skos:notation
RIV/00216224:14110/13:00069888!RIV14-MSM-14110___
n15:predkladatel
n16:orjk%3A14110
n3:aktivita
n18:I
n3:aktivity
I
n3:cisloPeriodika
5
n3:dodaniDat
n5:2014
n3:domaciTvurceVysledku
n9:8780757
n3:druhVysledku
n4:J
n3:duvernostUdaju
n6:S
n3:entitaPredkladatele
n17:predkladatel
n3:idSjednocenehoVysledku
94887
n3:idVysledku
RIV/00216224:14110/13:00069888
n3:jazykVysledku
n14:eng
n3:klicovaSlova
AML; allogeneic HSCT; age; donor
n3:klicoveSlovo
n7:allogeneic%20HSCT n7:age n7:donor n7:AML
n3:kodStatuVydavatele
SK - Slovenská republika
n3:kontrolniKodProRIV
[27A4D1DB339B]
n3:nazevZdroje
Neoplasma
n3:obor
n19:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
11
n3:rokUplatneniVysledku
n5:2013
n3:svazekPeriodika
60
n3:tvurceVysledku
Mužík, Jan Kozak, T. Sabty, F. A. Jindra, P. Szotkowski, T. Indrak, K. Zak, P. Karas, M. Koza, V. Raida, L. Cetkovsky, Petr
n3:wos
000322501800015
s:issn
0028-2685
s:numberOfPages
8
n8:doi
10.4149/neo_2013_075
n10:organizacniJednotka
14110